News

Engineered Receptors Help the Immune System Home in on Cancer

UCSF and University of Washington researchers developed synthetic receptors on the surface of immune cells that could make cancer immunotherapies more targeted

UCSF Treats First Patient with Homegrown Chimeric Antigen Receptor (CAR) T-cell Therapy

This month marked an important milestone for UCSF faculty and clinicians working to take on the challenge of glioblastoma multiforme (GBM). They treated their first patient with a promising chimeric antigen receptor (CAR) T-cell therapy that was fully conceived, designed, optimized and manufactured...

UCSF Scientists Build a Molecular ‘GPS’ to Guide Cell Therapies

Wendell Lim earns $30 million contract from ARPA-H to develop a cellular toolkit for therapies targeting diseases of the brain and lung.

New CRISPR Center Brings Hope for Rare and Deadly Genetic Diseases

CRISPR collaboration combines expertise from three UC schools to scale treatment for diseases that industry has largely passed by – until now.

Wiita Team Identifies a Novel Target for Acute Myeloid Leukemia

While immunotherapy has been successful for a number of aggressive cancers, acute myeloid leukemia (AML), a hematologic malignancy with dismal outcomes, has no currently known immunotherapy targets.

Thermo Fisher Scientific Opens Cell Therapy Facility at UCSF to Accelerate Development of Breakthrough Therapies

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and the University of California, San Francisco (UCSF), will accelerate advanced cell therapies for difficult to treat conditions, including cancer, rare diseases, and other illnesses, from a newly opened cGMP...

Can Lab-Grown Beta Cells Revolutionize Diabetes Care?

In high school, one of Julie Sneddon’s best friends had type 1 diabetes. Like the nearly one and a half million other Americans with the disease, her friend’s pancreas no longer made insulin – a hormone that regulates sugar levels in the body. Sneddon, PhD, now a UC San Francisco assistant...

The Long Road to Gene Therapy for Immunodeficient Children

Thanks to nearly 30 years of research and effort, another groundbreaking discovery has improved treatment for one of the most devastating genetic disorders affecting young children today.

$6M Gift from Family of Roblox Creator Launches New Initiative to Advance CAR T Therapy

UC San Francisco has launched the Baszucki Lymphoma Therapeutics Initiative to increase the effectiveness and availability of chimeric antigen receptor T-cell (CAR T) therapy for lymphoma patients. Jan Ellison Baszucki and her husband, Roblox CEO David Baszucki, gifted $6 million over five years to...

Living Therapeutics Initiative Announces Director of Scientific Programs

Cammie Edwards, PhD, has been appointed Director of Scientific Programs for the UCSF Living Therapeutics Initiative (LTI).